AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12169329 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular evoked myogenic potentials (VEMPs)
Number of subjects: 70
Study 12169329 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainstem auditory evoked potentials (BAEPs)
Number of subjects: 70
Study 12169329 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective visual vertical (SVV) evaluation
Number of subjects: 70
Study 12169329 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic eye movement recording
Number of subjects: 70
Study 9620251 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (hypofractionation, 5 Gy for fraction, 3-5 doses in one week)
Number of subjects: 0
Study 9620251 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (conventional fractionation)
Number of subjects: 0
Study 9620251 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (total dose lower than 34 Gy)
Number of subjects: 0
Study 9620251 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemoradiation
Number of subjects: 0
Study 9620251 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted infusional administration of 5FU concomitant to radiotherapy
Number of subjects: 0
Study 9620251 — intervention group
Group type: EXPERIMENTAL
Intervention: MeCCNU or Levamisole
Number of subjects: 0
Study 9620251 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy arm
Number of subjects: 0
Study 7971743 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of diazepam
Number of subjects: 12
Study 7971743 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of amitriptyline
Number of subjects: 12
Study 7971743 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of mirtazepine
Number of subjects: 12
Study 7971743 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam + Mirtazepine
Number of subjects: 12
Study 7971743 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 12
Study 7971743 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam + Amitriptyline
Number of subjects: 12
Study 7971743 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of zopiclone
Number of subjects: 12
Study 7971743 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of triazolam
Number of subjects: 12
Study 7971743 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg of ethanol
Number of subjects: 12
Study 7971743 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic-ethanol combinations
Number of subjects: 12
Study 7971743 — intervention group
Group type: EXPERIMENTAL
Intervention: Single drug intake
Number of subjects: 12
Study 7971743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2691677 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fitness
Number of subjects: 0
Study 2691677 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 0
Study 2691677 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 2691677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 0
Study 2691677 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 2691677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine
Number of subjects: 0
Study 2691677 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐adenosylmethionine
Number of subjects: 0
Study 2691677 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 4458774 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonated bupivacaine
Number of subjects: 0
Study 4458774 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain bupivacaine hydrochloride
Number of subjects: 0
Study 4458774 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride with adrenaline
Number of subjects: 0
Study 4458774 — intervention group
Group type: COMPARATOR
Intervention: All three preparations
Number of subjects: 0
Study 30642267 — intervention group
Group type: EXPERIMENTAL
Intervention: JBS3
Number of subjects: 240
Study 30642267 — intervention group
Group type: COMPARATOR
Intervention: QRISK®2
Number of subjects: 240
Study 27866449 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% of 2 cc MgSO4 in 2 cc of isotonic saline
Number of subjects: 100
Study 27866449 — intervention group
Group type: COMPARATOR
Intervention: 4 cc of isotonic saline
Number of subjects: 100
Study 25631070 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation plus SSAHT
Number of subjects: 106
Study 25631070 — intervention group
Group type: COMPARATOR
Intervention: SSAHT alone
Number of subjects: 106
Study 23218588 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus iscador (thrice weekly until tumour progression)
Number of subjects: 72
Study 23218588 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus iscador
Number of subjects: 72
Study 23218588 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control)
Number of subjects: 72
Study 21576029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilmapimod (15 mg/day)
Number of subjects: 50
Study 21576029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20092179 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous progenitor cells CD133+
Number of subjects: 42
Study 20092179 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytic fraction of the marrow (CD34+)
Number of subjects: 42
Study 20092179 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 42
Study 16443892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle therapy
Number of subjects: 1957
Study 16443892 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 1957
Study 16443892 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standard lifestyle advice
Number of subjects: 1957
Study 15567552 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine (VLF)
Number of subjects: 52
Study 15567552 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline (AMT)
Number of subjects: 52
Study 10836772 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated pamphlet decision-aid
Number of subjects: 257
Study 8841896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare toothbrush
Number of subjects: 60
Study 8841896 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 60
Study 1299491 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg/day)
Number of subjects: 1398
Study 1299491 — intervention group
Group type: COMPARATOR
Intervention: Control group (no calcium supplementation)
Number of subjects: 1398
Study 6386762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 35
Study 6386762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31495712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.44 mg/kg intravenous dose)
Number of subjects: 30
Study 31495712 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (1.7 ng/mL remifentanil)
Number of subjects: 30
Study 31460584 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC (1.2 g) + MTF (850-1500 mg/day)
Number of subjects: 53
Study 31460584 — intervention group
Group type: COMPARATOR
Intervention: UDCA (20 mg/kg) + MTF (850-1500 mg/day)
Number of subjects: 53
Study 31460584 — intervention group
Group type: COMPARATOR
Intervention: UDCA (15 mg/kg) + MTF (850-1500 mg/day)
Number of subjects: 53
Study 28705993 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3 g/day)
Number of subjects: 19
Study 28705993 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 19
Study 26265643 — intervention group
Group type: EXPERIMENTAL
Intervention: AREDS formulation followed by ranibizumab
Number of subjects: 5400
Study 26265643 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by ranibizumab
Number of subjects: 5400
Study 26265643 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by aflibercept
Number of subjects: 5400
Study 26265643 — intervention group
Group type: EXPERIMENTAL
Intervention: AREDS formulation followed by bevacizumab (monthly)
Number of subjects: 5400
Study 23821661 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 3002
Study 23821661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3002
Study 21486553 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosa advancement flap anoplasty
Number of subjects: 120
Study 21486553 — intervention group
Group type: COMPARATOR
Intervention: Fissurectomy
Number of subjects: 120
Study 19735180 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g n-3 PUFAs
Number of subjects: 135
Study 19735180 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g n-3 PUFAs
Number of subjects: 135
Study 19735180 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g n-3 PUFAs
Number of subjects: 135
Study 19735180 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 135
Study 16229957 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral dexamethasone
Number of subjects: 6
Study 16229957 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched healthy females), N=10
Number of subjects: 6
Study 15108768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) 2 mg/d
Number of subjects: 70
Study 15108768 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2 mg/kg/d
Number of subjects: 70
Study 10867596 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar macrophages (AM) from patients with pulmonary sarcoidosis
Number of subjects: 32
Study 10867596 — intervention group
Group type: COMPARATOR
Intervention: Alveolar macrophages (AM) from controls
Number of subjects: 32
Study 10867596 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide-stimulated AM from patients
Number of subjects: 32
Study 10867596 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocytes from patients
Number of subjects: 32
Study 10867596 — intervention group
Group type: COMPARATOR
Intervention: Monocytes from controls
Number of subjects: 32
Study 10867596 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐beta secretion from patients
Number of subjects: 32
Study 10867596 — intervention group
Group type: COMPARATOR
Intervention: TGF‐beta secretion from controls
Number of subjects: 32
Study 9112067 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium pyridoxal-5'-phosphate glutamate (MPPG) 450 mg daily for 8 weeks
Number of subjects: 23
Study 9112067 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium pyridoxal-5'-phosphate glutamate (MPPG) 600 mg daily for 8 weeks
Number of subjects: 23
Study 9112067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9112067 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium pyridoxal-5'-phosphate glutamate (MPPG)
Number of subjects: 23
Study 1576857 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (T = 25 pts)
Number of subjects: 49
Study 1576857 — intervention group
Group type: COMPARATOR
Intervention: Control (C = 24 pts)
Number of subjects: 49
Study 1576857 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (T)
Number of subjects: 49
Study 2864257 — intervention group
Group type: EXPERIMENTAL
Intervention: Short exercise with maximal work load
Number of subjects: 9
Study 2864257 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min exercise with half maximal work load
Number of subjects: 9
Study 2864257 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 10 min interval exercise
Number of subjects: 9
Study 2864257 — intervention group
Group type: COMPARATOR
Intervention: Control without exercise
Number of subjects: 9
Study 3314956 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg twice daily)
Number of subjects: 18
Study 3314956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29490103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sourdough croissants (SCs)
Number of subjects: 17
Study 29490103 — intervention group
Group type: COMPARATOR
Intervention: Brewer's yeast croissants (BCs)
Number of subjects: 17
Study 26492359 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh repair (trocar‐guided transobturator polypropylene and porcine dermis mesh)
Number of subjects: 117
Study 26492359 — intervention group
Group type: COMPARATOR
Intervention: Conventional repair
Number of subjects: 117
Study 25694364 — intervention group
Group type: EXPERIMENTAL
Intervention: FaceSay intervention
Number of subjects: 31
Study 25694364 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 23689085 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 475
Study 23689085 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 475
Study 20629109 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-specific nutrients (GSNs) administered for 1 month
Number of subjects: 50
Study 20629109 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-specific nutrients (GSNs)
Number of subjects: 50
Study 20629109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17991793 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (inspired Po(2) = 70 Torr)
Number of subjects: 5
Study 17233322 — intervention group
Group type: EXPERIMENTAL
Intervention: New lacquer containing phosphonic acid methacrylate
Number of subjects: 88
Study 17233322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 12763123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolytic therapy (ritodrine, indomethacin, calcium antagonists, magnesium sulphate)
Number of subjects: 0
Study 12763123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolytic therapy
Number of subjects: 0
Study 11077646 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly combination injectable contraceptive
Number of subjects: 0
Study 8828437 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal magnesium sulfate administered intrapartum
Number of subjects: 1189
Study 1380429 — intervention group
Group type: EXPERIMENTAL
Intervention: tropisetron 5mg once daily for 5 days
Number of subjects: 78
Study 1380429 — intervention group
Group type: COMPARATOR
Intervention: conventional antiemetic drugs
Number of subjects: 78
Study 6430706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combination of chemotherapy (cisplatinum, VP‐16, adriamycin) followed by radiotherapy
Number of subjects: 57
Study 6430706 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 57
Study 6430706 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (cisplatinum, VP‐16, adriamycin)
Number of subjects: 57
Study 30502929 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes used before hospitalization
Number of subjects: 1357
Study 30502929 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes used during hospitalization
Number of subjects: 1357
Study 30502929 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes used after discharge
Number of subjects: 1357
Study 30502929 — intervention group
Group type: EXPERIMENTAL
Intervention: Current e-cigarette users at 1 month
Number of subjects: 1357
Study 30502929 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular e-cigarette use
Number of subjects: 1357
Study 30502929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smoking among e-cigarette users
Number of subjects: 1357
Study 30502929 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of current e-cigarette use
Number of subjects: 1357
Study 29359398 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostascore = 2
Number of subjects: 702
Study 29359398 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostascore = 3
Number of subjects: 702
Study 29359398 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostascore = 4
Number of subjects: 702
Study 29359398 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostascore = 5
Number of subjects: 702
Study 29359398 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 702
Study 29359398 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 702
Study 29359398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-specific survival
Number of subjects: 702
Study 27254807 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC-HA
Number of subjects: 365
Study 27254807 — intervention group
Group type: COMPARATOR
Intervention: CMC
Number of subjects: 365
Study 25304191 — intervention group
Group type: EXPERIMENTAL
Intervention: WALK 2.0 website (with Web 2.0 features)
Number of subjects: 2894
Study 25304191 — intervention group
Group type: COMPARATOR
Intervention: 10,000 Steps website (with Web 1.0 features)
Number of subjects: 2894
Study 21965126 — intervention group
Group type: EXPERIMENTAL
Intervention: Education + PMR (E + P)
Number of subjects: 152
Study 21965126 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (E)
Number of subjects: 152
Study 21965126 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) (P)
Number of subjects: 152
Study 21965126 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 152
Study 19934029 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (200-1200 mg single-dose; 50-900 mg once daily for 14 days)
Number of subjects: 80
Study 19934029 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg
Number of subjects: 80
Study 19934029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19934029 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 80
Study 18573982 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine mesylate (0.4 mg per cartridge of local anesthetic)
Number of subjects: 122
Study 18573982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 16317361 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in referral strategies
Number of subjects: 184
Study 16317361 — intervention group
Group type: EXPERIMENTAL
Intervention: CuSum application
Number of subjects: 184
Study 11883025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocytocin (2.5 IU i.v. bolus)
Number of subjects: 602
Study 11883025 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (3 tablets per os)
Number of subjects: 602
Study 11883025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive measures)
Number of subjects: 602
Study 9600580 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen with glucose
Number of subjects: 104
Study 9600580 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen with placebo
Number of subjects: 104
Study 9600580 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 104
Study 9600580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 9600580 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 104
Study 7848353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ben-u-ron 500 mg suppositories
Number of subjects: 18
Study 7848353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ben-u-ron 1000 mg suppositories
Number of subjects: 18
Study 7848353 — intervention group
Group type: COMPARATOR
Intervention: Benuron tablets 500 mg
Number of subjects: 18
Study 3073806 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline sulphate (2 puffs of 250 micrograms each, separated by approximately 15 minutes)
Number of subjects: 10
Study 3073806 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 10
Study 31496537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 66
Study 31496537 — intervention group
Group type: COMPARATOR
Intervention: Plasma Radiofrequency Ablation (PRA)
Number of subjects: 66
Study 27822654 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsied embryos in RT group
Number of subjects: 236
Study 27822654 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsied embryos in rcp group
Number of subjects: 236
Study 25471688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1.5 μg/kg
Number of subjects: 50
Study 25471688 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline (placebo)
Number of subjects: 50
Study 23748928 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF) in scattered-site apartments
Number of subjects: 497
Study 23748928 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF) in a congregate setting (high needs only)
Number of subjects: 497
Study 23748928 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 497
Study 23748928 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF) in scattered-site apartments and congregate settings
Number of subjects: 497
Study 23748928 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF) in congregate setting (high needs only)
Number of subjects: 497
Study 21296449 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/m2 docetaxel (arm A)
Number of subjects: 73
Study 21296449 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/m2 docetaxel (arm B)
Number of subjects: 73
Study 21296449 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/m2 docetaxel (arm C)
Number of subjects: 73
Study 21296449 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/m2 escalated to 70 mg/m2 docetaxel (arm D)
Number of subjects: 73
Study 21296449 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 73
Study 19561338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan therapy
Number of subjects: 0
Study 19561338 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 0
Study 17873626 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTI-FREE RepleniSH Multi-Purpose Disinfecting Solution (regimen 1)
Number of subjects: 233
Study 17873626 — intervention group
Group type: COMPARATOR
Intervention: ReNu MultiPlus Multi-Purpose Solution No Rub Formula (regimen 2)
Number of subjects: 233
Study 17873626 — intervention group
Group type: COMPARATOR
Intervention: Complete MoisturePLUS Multi-Purpose Solution (regimen 3)
Number of subjects: 233